NCT05294055 Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma Status RECRUITING Phase PHASE2
NCT05289492 Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma Status TERMINATED Phase PHASE1
NCT05284591 Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv) Status COMPLETED Phase N/A
NCT05280275 A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible Status RECRUITING Phase PHASE1/PHASE2
NCT05276622 Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM) Status TERMINATED Phase N/A
NCT05272826 Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients Status RECRUITING Phase PHASE2
NCT05271682 A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma Status UNKNOWN Phase PHASE1
NCT05271630 Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant Status ACTIVE_NOT_RECRUITING Phase N/A
NCT05257083 A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05243797 Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Status RECRUITING Phase PHASE3
NCT05243342 A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma Status COMPLETED Phase PHASE1
NCT05243212 Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma Status RECRUITING Phase PHASE1/PHASE2
NCT05238311 Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) Status NO_LONGER_AVAILABLE Phase N/A
NCT05236621 A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma Status UNKNOWN Phase PHASE3
NCT05231629 Sequential Therapy in Multiple Myeloma Guided by MRD Assessments Status RECRUITING Phase PHASE2
NCT05228470 A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. Status COMPLETED Phase PHASE2
NCT05218603 Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT Status RECRUITING Phase N/A